Recently, first direct acting antiviral (DAA) against hepatitis C virus (HCV) has just approved in Japan. It is a first generation protease inhibitor, telaprevir. Telaprevir inhibits HCV NS3 & 4A serine protease, and combination with pegylated-interferon and ribavirin has now become a standard of care (SOC) for patients with genotype 1 high viral load hepatitis C. Fortunately, more than 50 new antivirals against HCV are under development including antivirals in preclinical trials. New antivirals are classified into several categories; (1) NS3 & 4A protease inhibitor, (2) NS5B polymerase inhibitor, (3) NS5A inhibitor, (4) host factor targeting antivirals, (5) interferon-related antivirals, and others. Combination of different classes of antivirals without interferon is expected to become a future SOC for hepatitis C.